NEW YORK (AP) — Teva Pharmaceutical Industries Ltd. said Tuesday it began selling a generic injectable version of Eloxatin, a chemotherapy drug, after the Food and Drug Administration approved the product. Teva said it began selling 50 milligram and 100 mg doses of the drug, also called oxaliplatin. The company said U.S. sales of Eloxatin totaled $1.3 billion in 2008. The branded version of the drug is approved to treat advanced colon cancer and stage III colon cancer following surgery. Eloxatin is marketed by Sanofi-Aventis of France. Hospira Inc. also received FDA approval for a generic oxaliplatin injection on Tuesday, and began shipping the product. Sanofi-Aventis is suing both Teva and Hospira for patent infringement.